Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Abate Daga, Daniel ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BLUEBIRD BIO   (United States)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptors (CAR); Pancreatic cancer; PSCA; Synthetic biology

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE MODEL; FIBROBLAST; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PANCREAS CANCER; POLARIZATION; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR XENOGRAFT;

EID: 84906517258     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.29194     Document Type: Article

References (10)

1. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116:4099-102; PMID:20668228; http://dx.doi. org/10.1182/blood-2010-04-281931
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/ NEJMoa1103849
3. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:77ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
4. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14:1264-70; PMID:18978797; http://dx.doi. org/10.1038/nm.1882
5. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2:112-20; PMID:24579088; http://dx.doi.org/10.1158/2326-6066.CIR-13-0170
6. Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1:26-31; http://dx.doi.org/10.1158/2326-6066.CIR-13-0006
7. Abate-Daga D, Lagisetty KH, Tran E, et al. A novel chimeric antigen receptor against PSCA mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014; (Forthcoming); http://dx.doi.org/10.1089/ hum.2013.209
8. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013; 5:ra172; PMID:24337479; http://dx.doi.org/10.1126/scitranslmed.3006597
9. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-83; PMID:22047558; http://dx.doi. org/10.1056/NEJMoa1106152
10. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med 2013; 5:ps7; PMID:23552369; http://dx.doi. org/10.1126/scitranslmed.3005568